Biotechnology Industry · global
Consumables Support Growth as Equipment Demand Recovers: Sartorius Stedim Reports Higher Revenue for First Nine Months
The biopharmaceutical manufacturing supply chain is showing signs of improving demand, but tariff compensation reduced reported revenue growth. The supplier maintained its full-year outlook, and its results offer a window into drugmakers’ production and equipment purchasing.
Changes in demand for biopharmaceutical manufacturing often show up first in suppliers’ sales of consumables and equipment. Sartorius Stedim Biotech announced its results for the first nine months of 2026 on October 22. Consumables continued to drive growth, while bioprocessing equipment sales also increased from the same period last year. Growth in both businesses provides a positive signal for manufacturing demand, but is not yet sufficient to conclude that the entire industry is broadly expanding investment.
The company’s revenue for the first nine months was approximately €2.289 billion, up 4.3% on a reported basis and 6.5% excluding currency effects. After also excluding the impact of tariff compensation paid to customers, what the company calls operational revenue growth was 7.8%. These figures reflect different calculation bases and cannot be used interchangeably.
The difference stems from customer compensation totaling €28 million. According to the company’s announcement and material published on Webdisclosure, after obtaining tariff refunds, the company compensated customers who had previously paid the related surcharges. For accounting purposes, this reduced both revenue and cost of sales, lowering revenue growth without affecting profit. Revenue in the Asia-Pacific region for the first nine months was approximately €524 million, up 10.6% at constant currencies, with the Chinese market also making a positive contribution.
Quarterly performance also improved. Financial results data compiled by S&P Capital IQ and carried by MarketScreener showed third-quarter revenue of €762.1 million, compared with €705.7 million in the same period last year. Net profit increased from €64.2 million to €95.5 million. Net profit for the first nine months totaled €276.6 million, up 26.7% year over year, indicating that profit grew faster than revenue.
However, net profit and measures of underlying operating profitability still need to be considered separately. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) for the first nine months were €716 million, up 4.8% year over year, while the margin rose from 31.1% to 31.3%. Operating cash flow increased 11.6% to approximately €498 million, and free cash flow rose 58.5% to approximately €264 million. The company said the latter benefited from improved cash inflows and also reflected lower investment spending.
Management maintained its full-year expectations for revenue growth of 6% to 10% at constant currencies and an adjusted EBITDA margin slightly above 31%, while lowering its projected capital expenditure-to-revenue ratio from 13.3% to approximately 13%. The company expects full-year operational growth excluding tariff compensation to fall in the middle of the range, with growth including the compensation in the lower half of the range.
The most significant industry signal in these results is that recurring consumables purchases remain supportive, while equipment demand continues to improve. However, the announcement did not provide sufficiently detailed breakdowns to assess the breadth of equipment growth, and the financial figures have not been audited or reviewed. For the biopharmaceutical manufacturing market, these results offer a view of demand at one major supplier; changes in trade policy and customers’ subsequent purchases could still alter the pace of growth.